Anshul Maheshwari Sells 4,937 Shares of SI-BONE, Inc. (NASDAQ:SIBN) Stock

SI-BONE, Inc. (NASDAQ:SIBN) CFO Anshul Maheshwari sold 4,937 shares of the company’s stock in a transaction on Monday, May 12th. The stock was sold at an average price of $19.02, for a total value of $93,901.74. Following the sale, the chief financial officer now owns 232,069 shares of the company’s stock, valued at $4,413,952.38. This trade represents a 2.08% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Anshul Maheshwari also recently made the following trade(s):

• On Wednesday, May 7th, Anshul Maheshwari sold 4,937 shares of SI-BONE stock. The stock was sold at an average price of $17.00, for a total value of $83,929.00.

SI-BONE Stock Up 4.8%

SIBN stock opened at $19.79 on Friday. The company has a debt-to-equity ratio of 0.22, a quick ratio of 7.22 and a current ratio of 8.25. The company has a market capitalization of $843.35 million, a price-to-earnings ratio of -21.51 and a beta of 0.82. SI-BONE, Inc. has a fifty-two week low of $11.70 and a fifty-two week high of $20.05. The stock has a fifty day moving average of $14.83 and a 200-day moving average of $15.02.

SI-BONE (NASDAQ:SIBN) last posted its quarterly earnings results on Monday, May 5th. The company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.24) by $0.09. The company had revenue of $47.29 million during the quarter, compared to the consensus estimate of $45.13 million. SI-BONE had a negative return on equity of 22.51% and a negative net margin of 23.82%. As a group, equities research analysts predict that SI-BONE, Inc. will post -0.78 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in SI-BONE by 4.4% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,373 shares of the company’s stock worth $328,000 after purchasing an additional 988 shares during the period. Invesco Ltd. boosted its stake in SI-BONE by 8.9% in the 4th quarter. Invesco Ltd. now owns 17,203 shares of the company’s stock worth $241,000 after purchasing an additional 1,413 shares during the period. Rhumbline Advisers boosted its stake in SI-BONE by 3.0% in the 4th quarter. Rhumbline Advisers now owns 57,621 shares of the company’s stock worth $808,000 after purchasing an additional 1,683 shares during the period. ANTIPODES PARTNERS Ltd bought a new position in SI-BONE in the 1st quarter worth about $34,000. Finally, Barclays PLC boosted its stake in SI-BONE by 2.7% in the 4th quarter. Barclays PLC now owns 99,212 shares of the company’s stock worth $1,391,000 after purchasing an additional 2,589 shares during the period. Institutional investors own 98.11% of the company’s stock.

Analyst Ratings Changes

Several research analysts have weighed in on the company. Cantor Fitzgerald reissued an “overweight” rating and issued a $25.00 price objective on shares of SI-BONE in a research report on Tuesday, May 6th. Needham & Company LLC reissued a “buy” rating and issued a $24.00 price objective on shares of SI-BONE in a research report on Tuesday, May 6th. Finally, Truist Financial boosted their price objective on SI-BONE from $20.00 to $22.00 and gave the stock a “buy” rating in a research report on Tuesday, May 6th.

About SI-BONE

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.